SOST and osteoporosis: In osteoporosis, one of the most prevalent bone diseases worldwide, a monoclonal antibody inhibiting sclerostin known as romosozumab, was shown to reduce the risk for vertebral fractures in postmenopausal women within a 12 months period [77].